Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 102kWORD 16k
16 November 2016
Question for written answer E-008598-16
to the Commission
Rule 130
Nicola Caputo (S&D) , Monica Macovei (ECR)

 Subject:  Antibiotic resistance
 Answer in writing 

Over the past few days, the WHO has sounded the alarm for the umpteenth time about the widespread epidemic of antibiotic resistance.

One of the main causes is the improper administration of these medicines, which has led to worrying statistics, especially in Italy and Germany: + 79% between 2000 and 2010.

This has been accompanied by a decline in medical research: in 1990, 18 major pharmaceutical companies were active in this sector, while in 2010 the figure was only four. Indeed, there were 16 new antibiotics in the period 1983-1987, 10 between 1993 and 1997 and five between 2003 and 2007.

Can the Commission therefore answer the following questions:

Does it not agree that more funding needs to be granted to public research bodies in the field of structural biology, biochemistry and molecular biology, in order to identify and develop additional new molecules?
Does it not consider it necessary to update its 2001 Community strategy against antibiotic resistance, by providing for measures to increase citizens’ sense of responsibility with regard to the use of antibiotics?
Should it not promote good practice for the control of hospital infections and research into rapid tests to identify the nature and origin of the infections?

Original language of question: IT 
Legal notice